Prosecution Insights
Last updated: April 19, 2026
Application No. 18/208,862

DIPYRROLIDINE-1-ONE COMPOUNDS AND THEIR PREPARATION METHOD

Non-Final OA §102§DP
Filed
Jun 12, 2023
Examiner
SANCHEZ, JUSTIN CHRISTOPHER
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Wuhan Jianmin Dapeng Pharmaceutical Co. Ltd.
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
3y 5m
To Grant
94%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
27 granted / 32 resolved
+24.4% vs TC avg
Moderate +10% lift
Without
With
+10.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
27 currently pending
Career history
59
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
29.0%
-11.0% vs TC avg
§102
19.1%
-20.9% vs TC avg
§112
31.6%
-8.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 32 resolved cases

Office Action

§102 §DP
DETAILED ACTION Claims 1-10, submitted 25 February 2026, are pending in the application. Claims 9-10 are withdrawn. Claims 1-8 are under examination in the instant Office Action. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Invention II, claims 4-8, in the reply filed on 25 February 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1-3 and 9-10 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 25 February 2026. Claims 4-8 are allowable. The restriction requirement between Inventions I-III, as set forth in the Office action mailed on 29 December 2025, has been reconsidered in view of the allowability of claims to the elected invention pursuant to MPEP § 821.04(a). The restriction requirement is hereby withdrawn as to any claim that requires all the limitations of an allowable claim. Specifically, the restriction requirement of Invention I is withdrawn. Claims 1-3, directed to a dipyrrolidine-1-one compound of formula I are no longer withdrawn from consideration because the claim(s) requires all the limitations of an allowable claim. However, claims 9-10, directed to a method for treating a tumor are withdrawn from consideration because they do not require all the limitations of an allowable claim. In view of the above noted withdrawal of the restriction requirement, applicant is advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. In summary, claims 1-8 are under consideration in the instant office action and claims 9-10 remain withdrawn. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kinoshita et al. ("A New and Convenient Wittig-type Reaction for the Preparation of Pyrromethenone Derivative." Chemistry letters 22.8 (1993): 1441-1442.). Kinoshita teaches a compound identical to that of the Applicant which reads on the limitations of instant claim 1. Kinoshita exemplifies the compound, shown below, which reads on the limitations of the genus of instant claim 1 when R = C-1 alkyl (i.e., methyl); R1 = p-toluene sulfide; and R2 = alkoxycarbonyl (i.e., tert-butyloxycarbonyl). Compound VIII taught by Kinoshita PNG media_image1.png 134 242 media_image1.png Greyscale (pg. 1, Compound VIII) Compound 1c taught by Applicant PNG media_image2.png 83 241 media_image2.png Greyscale (Claim 3, Compound 1c) Allowable Subject Matter Claims 4-8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The closest prior art is Kinoshita, which teaches a method of preparing a dipyrromethenone compound which is identical to that of the Applicant. However, the method taught by Kinoshita requires a different substrate and requires the removal of a the SO2-Tol, shown below. PNG media_image3.png 517 654 media_image3.png Greyscale Conclusion Claims 1-3 are rejected. Claims 4-8 are objected to. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JUSTIN CHRISTOPHER SANCHEZ whose telephone number is (703)756-5336. The examiner can normally be reached Monday -Friday (0730-1700). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JUSTIN CHRISTOPHER SANCHEZ Examiner Art Unit 1622 /J.C.S./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jun 12, 2023
Application Filed
Mar 18, 2026
Non-Final Rejection — §102, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594271
COMBINATION THERAPY FOR CANCER
2y 5m to grant Granted Apr 07, 2026
Patent 12558348
BIOACTIVE PHYTOCHEMICALS
2y 5m to grant Granted Feb 24, 2026
Patent 12551463
DOSING OF A BRUTON'S TYROSINE KINASE INHIBITOR
2y 5m to grant Granted Feb 17, 2026
Patent 12551471
ABT-751 AND IONIZING RADIATION
2y 5m to grant Granted Feb 17, 2026
Patent 12527753
Cysteamine for the Treatment, Mitigation and Prevention of Coronaviral, e.g., SARS-CoV-2, Infections
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
94%
With Interview (+10.0%)
3y 5m
Median Time to Grant
Low
PTA Risk
Based on 32 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month